ArticleClinical and experimental medicine2019
Association between IL-35 and coronary arterial lesions in children with Kawasaki disease.
Article in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.Life (Basel, Switzerland) · 2025Review
- Kawasaki disease: insights into the roles of T cells.Frontiers in immunology · 2025Review
- Association Between Thymosin β4 and Coronary Arterial Lesions in Children with Kawasaki Disease.Journal of inflammation research · 2025Article
- Prokineticin 2 as a potential biomarker for the diagnosis of Kawasaki disease.Clinical and experimental medicine · 2023Article
- Interaction of S100A6 Protein with the Four-Helical Cytokines.Biomolecules · 2023Article
- Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.Inflammation · 2023Article
- Reappraisal of VEGF in the Pathogenesis of Kawasaki Disease.Children (Basel, Switzerland) · 2022Article
- Characterization of Inflammatory Factors and T Cell Subpopulations in a Murine Model of Kawasaki Disease Induced by Candida albicans Cell Wall Extracts (CAWS).Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Red Blood Cell Distribution Width as a Predictive Marker for Coronary Artery Lesions in Patients with Kawasaki Disease.Pediatric cardiology · 2021Article
- Effect of Activin A on activation status of monocytes in acute-phase Kawasaki disease.Clinical and experimental medicine · 2021Article
- The diagnostic role of AIM2 in Kawasaki disease.Clinical and experimental medicine · 2021Article
- Expression of inflammatory factors and oxidative stress markers in serum of patients with coronary heart disease and correlation with coronary artery calcium score.Experimental and therapeutic medicine · 2020Article
- The effects of phenanthrene exposure on Treg and Th17 cells related cytokines in female rats.Toxicology research · 2020Article
- Increased Interleukin-35 suppresses peripheral CD14BMC immunology · 2020Article
- Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities.Clinical and experimental medicine · 2020Article
- Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease.Clinical and experimental medicine · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Kawasaki disease (KD) arises due to the acute inflammation and immune system dysfunction. This study investigated the relationship between the serum level of IL-35 and coronary artery lesions (CALs) in patients with KD. We obtained blood samples from 90 children with KD before intravenous immunoglobulin therapy. Levels of IL-35, IL-6, IL-17A, IL-10, MCP-1 and VEGF were measured in 190 cases, including 4 groups: KD with coronary arterial lesions (n = 46), KD without coronary arteries lesions (n = 44), febrile control group (FC, n = 40) and the normal control group (NC, n = 60). White blood cell counts (WBC), red blood cell counts (RBC), hemoglobin, platelet, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and procalcitonin were tested in all subjects. Levels of IL-35, RBC and hemoglobin significantly decreased, and IL-6, IL-17A, IL-10, MCP-1 and VEGF were significantly elevated in the KD group compared with febrile and control groups. IL-35 serum level even decreased, and ESR, IL-6, MCP-1 and VEGF increased in the KD patients with CALs. Serum levels of IL-35 in KD patients were negatively associated with WBC, CRP, IL-6, IL-17A, IL-10, MCP-1 and VEGF in children with KD. IL-35 may have the effect on inhibiting inflammatory process in KD and further preventing KD patients from coronary artery lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.